Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition.

Tarrado-Castellarnau M, de Atauri P, Tarragó-Celada J, Perarnau J, Yuneva M, Thomson TM, Cascante M.

Mol Syst Biol. 2017 Oct 4;13(10):940. doi: 10.15252/msb.20167321.


Oncogenic regulation of tumor metabolic reprogramming.

Tarrado-Castellarnau M, de Atauri P, Cascante M.

Oncotarget. 2016 Sep 20;7(38):62726-62753. doi: 10.18632/oncotarget.10911. Review.


Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.

Tarrado-Castellarnau M, Cortés R, Zanuy M, Tarragó-Celada J, Polat IH, Hill R, Fan TW, Link W, Cascante M.

Pharmacol Res. 2015 Dec;102:218-34. doi: 10.1016/j.phrs.2015.09.009. Epub 2015 Nov 4.


A novel cyclometallated Pt(II)-ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation.

Cortés R, Tarrado-Castellarnau M, Talancón D, López C, Link W, Ruiz D, Centelles JJ, Quirante J, Cascante M.

Metallomics. 2014 Mar;6(3):622-33. doi: 10.1039/c3mt00194f. Epub 2014 Feb 3.


Targeting cell cycle regulation in cancer therapy.

Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M.

Pharmacol Ther. 2013 May;138(2):255-71. doi: 10.1016/j.pharmthera.2013.01.011. Epub 2013 Jan 26. Review.


Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation.

Diaz-Moralli S, Tarrado-Castellarnau M, Alenda C, Castells A, Cascante M.

PLoS One. 2011;6(9):e25323. doi: 10.1371/journal.pone.0025323. Epub 2011 Sep 27.

Supplemental Content

Loading ...
Support Center